Imam A, Stathopoulos E, Holland S L, Epstein A L, Taylor C R
Department of Pathology, University of Southern California School of Medicine, Los Angeles 90033.
Cancer Res. 1990 Mar 1;50(5):1650-7.
An antigen specifically expressed on the surface of plasma membrane of B-lymphocytes and Reed-Sternberg cells was identified using a newly developed monoclonal antibody produced by immunization by BALB/c mouse with a Hodgkin's cell line (HDLM-3). The antibody was termed anti-BLA.36 (B lymphocyte antigen.36) to indicate its predominant reactivity and the molecular weight of the corresponding antigen. By using immunoperoxidase techniques, expression of BLA.36 was detected on Hodgkin's, B-, and pre-B-cell lines, but not on other hematopoietic, melanoma, or carcinoma cell lines. In normal tissues, BLA.36 was detectable predominantly on cells in the germinal center and mantle zone of reactive follicles in lymph nodes and spleen. In hematopoietic malignancy, BLA.36 was detectable on the surface of Reed-Sternberg cells, mononuclear Hodgkin's cells, and also on malignant cells of B-cell lineage. Under these conditions, T-lymphocytes, histiocytes, granulocytes, macrophages, stromal cells in lymphoid tissue, and both normal and neoplastic epithelial cells were consistently negative for the expression of the antigen, with the single exception of a variable proportion of Kupffer cells in normal liver. Biochemical and immunological analyses indicate that BLA.36 is distinct from previously identified antigens of hematopoietic cell lineage, including CD20 and CD75 (LN2) which have similar molecular weights. When BLA.36-positive cell lines were cultured in the presence of the antibody, cell growth was adversely affected. Such an effect was eliminated by removal of the antibody from the culture, suggesting a possible growth-related function of the antigen. Anti-BLA.36 may serve as a probe to study growth-related functions of the corresponding antigen during normal growth of the B-lymphocyte, as well as in the neoplastic proliferations occurring in Hodgkin's disease and antigen-positive B-cell lymphomas. Finally, the antibody has already demonstrated its usefulness for the identification of Reed-Sternberg and Hodgkin's cells, and also normal and malignant B-lymphocytes in frozen as well as formalin- or B5-fixed/paraffin-embedded tissue sections.
利用一种新开发的单克隆抗体鉴定出一种在B淋巴细胞和里德-斯腾伯格细胞的质膜表面特异性表达的抗原。该单克隆抗体是通过用霍奇金细胞系（HDLM-3）免疫BALB/c小鼠产生的。该抗体被命名为抗BLA.36（B淋巴细胞抗原36），以表明其主要反应性及相应抗原的分子量。通过免疫过氧化物酶技术检测到，BLA.36在霍奇金细胞系、B细胞系和前B细胞系中表达，但在其他造血细胞系、黑色素瘤细胞系或癌细胞系中不表达。在正常组织中，BLA.36主要在淋巴结和脾脏中反应性滤泡的生发中心和套区的细胞上可检测到。在造血系统恶性肿瘤中，里德-斯腾伯格细胞、单核霍奇金细胞以及B细胞系恶性细胞的表面均可检测到BLA.36。在这些情况下，T淋巴细胞、组织细胞、粒细胞、巨噬细胞、淋巴组织中的基质细胞以及正常和肿瘤上皮细胞对抗原表达始终呈阴性，正常肝脏中可变比例的库普弗细胞是唯一的例外。生化和免疫分析表明，BLA.36与先前鉴定的造血细胞系抗原不同，包括分子量相似的CD20和CD75（LN2）。当BLA.36阳性细胞系在抗体存在的情况下培养时，细胞生长受到不利影响。通过从培养物中去除抗体可消除这种影响，这表明该抗原可能具有与生长相关的功能。抗BLA.36可作为一种探针，用于研究B淋巴细胞正常生长过程中以及霍奇金病和抗原阳性B细胞淋巴瘤中发生的肿瘤增殖过程中相应抗原与生长相关的功能。最后，该抗体已证明其在鉴定里德-斯腾伯格细胞和霍奇金细胞以及冷冻以及福尔马林或B5固定/石蜡包埋组织切片中的正常和恶性B淋巴细胞方面的有用性。
